U.S. Markets open in 9 hrs 28 mins

Aprea Therapeutics, Inc. (APRE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.9960+0.0730 (+7.91%)
At close: 04:00PM EDT
0.9401 -0.06 (-5.61%)
After hours: 05:20PM EDT

Aprea Therapeutics, Inc.

535 Boylston St.
Boston, MA 02116
United States

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Oren Gilad Ph.D.Co-Founder, Chief Exec. Officer, Pres and DirectorN/AN/AN/A
Dr. Kevin D. SmithCo-Founder, Director and AdvisorN/AN/AN/A
Dr. Dansu LiHead of TechnologyN/AN/AN/A
Dr. Rifat Pamukcu M.D.Chief Medical Advisor and DirectorN/AN/A1958
Mr. Hank BreslinHead of Medicinal ChemistryN/AN/AN/A
Dr. Michel AfarganHead of Pharmacology Devel.N/AN/AN/A
Ms. Andrea EpsteinControllerN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.

Corporate Governance

Aprea Therapeutics, Inc.’s ISS Governance QualityScore as of July 1, 2022 is 8. The pillar scores are Audit: 4; Board: 9; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.